Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study
Cancer Cell · 2026-06 · 44 (6) · 1147-1159.e6
DOI: 10.1016/j.ccell.2026.03.017 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2026-06. Verfasst von David Planchard und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France; IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor, Immunoconjugates. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency, Institut Gustave-Roussy, Daiichi Sankyo Chemical Pharma Co Ltd.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) are rapidly transforming the treatment landscape of advanced non-small cell lung cancer (NSCLC), yet validated predictive biomarkers to guide their use remain lacking. ICARUS-LUNG01 is a prospective, phase II study designed to integrate clinical outcomes with longitudinal translational analyses. In this multicenter trial, 100 pretreated patients with advanced NSCLC received the TROP2-directed ADC datopotamab deruxtecan (Dato-DXd). The study reported an objective response rate (ORR) of 26.0%, with a median progression-free survival (PFS) of 3.6 months, and a greater benefit observed in non-squamous tumors. Baseline and on-treatment tumor analyses suggested that resistance to Dato-DXd could be associated with a lack of TROP2 cytoplasmic staining and the early activation of DNA repair pathways. Conversely, the activation of immune-related pathways was associated with treatment response. Validation of these findings in phase III studies will be essential to define biomarkers, ultimately enabling more precise identification of patients most likely to benefit from Dato-DXd.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France; IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94800 Villejuif, France.
- IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94800 Villejuif, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Oncostat INSERM U1018, Université Paris-Saclay, Labeled Ligue…
- Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France; IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94800 Villejuif, France; INSERM U981, Université Paris-Saclay, IHU PRISM…
- IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94800 Villejuif, France; INSERM 1279, Gustave Roussy, 94800 Villejuif, France.
- IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94800 Villejuif, France; INSERM U981, Université Paris-Saclay, IHU PRISM, 94800 Villejuif, France; CentraleSupélec, Inria, Université Paris-Sacla…
- IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, 94800 Villejuif, France; INSERM U981, Université Paris-Saclay, IHU PRISM, 94800 Villejuif, France.
Förderung
- French National Research Agency
- Institut Gustave-Roussy
- Daiichi Sankyo Chemical Pharma Co Ltd
Zitieren
APA
Planchard, D., Cozic, N., Mosele, M. F., Corcos, N., Le Bescond, L., Pradat, Y., Ghigna, M. R., Nachabeh, G., Alfaro, A., Catelain, C., Job, B., Mami-Chouaib, F., Badel, S., Corgnac, S., Farace, F., Oulhen, M., Kannouche, P., Ngoc Tran, D. T., Droin, N., …, & Pistilli, B. (2026). Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell, 44(6), 1147-1159.e6. https://doi.org/10.1016/j.ccell.2026.03.017
Vancouver
Planchard D, Cozic N, Mosele MF, Corcos N, Le Bescond L, Pradat Y, et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell. 2026;44(6):1147-1159.e6. doi:10.1016/j.ccell.2026.03.017
BibTeX
@article{Planchard2026,
author = {Planchard, David and Cozic, Nathalie and Mosele, Maria Fernanda and Corcos, Noemie and Le Bescond, Loic and Pradat, Yoann and Ghigna, Maria Rosa and Nachabeh, Ghada and Alfaro, Alexia and Catelain, Cyril and Job, Bastien and Mami-Chouaib, Fathia and Badel, Severine and Corgnac, Stephanie and Farace, Françoise and Oulhen, Marianne and Kannouche, Patricia and Ngoc Tran, Diep Thi and Droin, Nathalie and Wislez, Marie and Chouaid, Christos and Curcio, Hubert and Cousin, Sophie and Mascaux, Celine and Cadranel, Jacques and Geier, Margaux and Cheikh-Hussin, Rasha and Guyader, Pierre and Signolle, Nicholas and Godefroy, Karine and Talbot, Hugues and Vakalopoulou, Maria and Christodoulidis, Stergios and Bernard, Elsa and Koudou, Yves and Camara, Valerie and Belarkemi, Abdelhafidh and Klein, Alexis and Morretton, Jean Philippe and East, Philip and Chiaverelli, Rachel and Zwirtes, Ricardo and Michiels, Stefan and Barlesi, Fabrice and André, Fabrice and Montagnac, Guillaume and Pistilli, Barbara},
title = {Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {6},
pages = {1147--1159.e6},
doi = {10.1016/j.ccell.2026.03.017}
}
EUVIMED